Sagimet Biosciences receives FDA nod to begin testing its therapy for acne

Reuters
11 Mar
March 11 (Reuters) - Sagimet Biosciences Inc ::
*SAGIMET BIOSCIENCES ANNOUNCES CLEARANCE OF IND FOR FASN INHIBITOR TVB-3567, TO BE DEVELOPED FOR THE TREATMENT OF ACNE
*SAGIMET BIOSCIENCES INC - FIRST-IN-HUMAN PHASE 1 TRIAL OF TVB-3567 PLANNED IN 2025

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 11-MAR-202512:00:03.297 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10